Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus according to the World Health Organization (WHO) criteria treated with basal insulin and up to 3 of the following oral antihyperglycemic medication (OAM):~  * dipeptidyl peptidase-4 (DPP-4) inhibitors~ * sodium-glucose cotransporter (SGLT-2) inhibitors~ * biguanides~ * alpha-glucosidase inhibitors~ * sulfonlyureas~* HbA1c value of 6.5% to 10%, inclusive~* Body mass index (BMI) between 20 and 45 kilograms per meter squared (kg/m2), inclusive~Exclusion Criteria:~* Type 1 diabetes mellitus or latent autoimmune diabetes~* Any episodes of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening~* Any of the following cardiovascular (CV) conditions: acute myocardial infarction, New York Heart Association Class III or IV heart failure, or cerebrovascular accident (stroke)~* Acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease~* Estimated glomerular filtration rate (eGFR) \<30 milliliters/minute/1.73 m2~* Active or untreated malignancy~* Chronic (\>14 days) systemic glucocorticoid therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY3209590 Algorithm 1 (Type: EXPERIMENTAL): Participants received loading dose followed by weekly dose of LY3209590 based on the prior randomization basal insulin dose for a period of 32 weeks by subcutaneous (SC) injection. Dose titration was done to maintain fasting blood glucose of \<140 milligram per deciliter (mg/dL).
- LY3209590 Algorithm 2 (Type: EXPERIMENTAL): Participants received loading dose followed by weekly dose of LY3209590 based on the prior randomization basal insulin dose for a period of 32 weeks by subcutaneous injection. Dose titration was done to maintain fasting blood glucose of \<120 mg/dL.
- Insulin Degludec (Type: ACTIVE_COMPARATOR): Participants received same dose of Degludec as the total basal insulin dose already administered prior to randomization. Dose was titrated to maintain fasting blood glucose of ≤100 mg/dL to achieve glycemic goal of HbA1C \<7%.

Based on this trial design, predict the completion outcome and termination type (if applicable).